Episoder
-
Join Drs Benjamin Schlechter and Martin Dib as they discuss cutting-edge transplant techniques to treat colorectal cancer.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000094. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Colorectal Cancer: Prevention, Diagnosis, and Therapeutic Options https://reference.medscape.com/slideshow/colorectal-cancer-6007241
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients With Cirrhosis https://pubmed.ncbi.nlm.nih.gov/8594428/
Chemotherapy and Liver Transplantation Versus Chemotherapy Alone in Patients With Definitively Unresectable Colorectal Liver Metastases: A Prospective Multicentric Randomized Trial (TRANSMET) https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3500
Safety and Feasibility of Chemotherapy Followed by Liver Transplantation for Patients With Definitely Unresectable Colorectal Liver Metastases: Insights From the TransMet Randomised Clinical Trial https://pubmed.ncbi.nlm.nih.gov/38721015/
Liver Transplantation for Hepatic Metastases From Colorectal Cancer: Current Knowledge and Open Issues https://pubmed.ncbi.nlm.nih.gov/36672295/
Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/23360920/
Survival Following Liver Transplantation for Patients With Nonresectable Liver-Only Colorectal Metastases https://pubmed.ncbi.nlm.nih.gov/31188200/
Carcinoembryonic Antigen https://www.ncbi.nlm.nih.gov/books/NBK578172/
BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies https://pubmed.ncbi.nlm.nih.gov/36077604/
Perioperative Management of the Patient With Liver Disease https://emedicine.medscape.com/article/284667-overview
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration https://pubmed.ncbi.nlm.nih.gov/36675641/
R0 Liver Resection Should Be a First-Line Treatment for Selected Patients With Intermediate Hepatocellular Cancer https://pubmed.ncbi.nlm.nih.gov/37408800/
-
Join Drs Benjamin Schlechter and Jeff Meyerhardt as they discuss the latest breakthroughs in adjuvant chemo for CRC and share their decision-making in real-world scenarios.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000093. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Colorectal Cancer: Prevention, Diagnosis, and Therapeutic Options https://reference.medscape.com/slideshow/colorectal-cancer-6007241
Colon Cancer https://emedicine.medscape.com/article/277496-overview
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer https://pubmed.ncbi.nlm.nih.gov/15175436/
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/29590544/
Overall Survival With 3 or 6 Months of Adjuvant Chemotherapy in Italian TOSCA Phase 3 Randomised Trial https://pubmed.ncbi.nlm.nih.gov/33098997/
3 Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Combination Therapy for Colorectal Cancer (SCOT): An International, Randomised, Phase 3, Non-Inferiority Trial https://pubmed.ncbi.nlm.nih.gov/29611518/
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin as First-Line Therapy for Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/18421053/
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials https://pubmed.ncbi.nlm.nih.gov/36306483/
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database https://pubmed.ncbi.nlm.nih.gov/23733765/
Comparative Effectiveness of Oxaliplatin vs Non-Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/22266473/
Role of Physical Activity and Diet After Colorectal Cancer Diagnosis https://pubmed.ncbi.nlm.nih.gov/25918293/
Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/17699009/
Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone as Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 https://pubmed.ncbi.nlm.nih.gov/17687149/
Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II) https://pubmed.ncbi.nlm.nih.gov/35014958/
-
Manglende episoder?
-
Join Drs Benjamin Schlechter and Joshua Smith as they discuss the evolution of nonoperative rectal cancer management and organ preservation, highlighting groundbreaking trials like OPRA and JANUS.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000092. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients With Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/38712176/
Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-Term Results https://pubmed.ncbi.nlm.nih.gov/15383798/
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial https://pubmed.ncbi.nlm.nih.gov/37883738/
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) https://pubmed.ncbi.nlm.nih.gov/37270691/
Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial https://pubmed.ncbi.nlm.nih.gov/30192323/
Overall Survival After Treatment Failure Among Patients With Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/37902752/
Short-Course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33301740/
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial https://pubmed.ncbi.nlm.nih.gov/36661037/
Neoadjuvant Chemotherapy With FOLFIRINOX and Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33862000/
Phase III Trial of Short-Course Radiotherapy Followed by CAPOXIRI Versus CAPOX in Locally Advanced Rectal Cancer: The ENSEMBLE Trial https://www.esmogastro.org/article/S2949-8198(23)00003-1/fulltext
-
Join Drs Benjamin Schlechter and Cathy Eng as they discuss the treatments and clinical trials available for patients with refractory colorectal cancer.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000091. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/25970050/
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/37133585/
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/23177514/
Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Asian Patients With Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/25981818/
Regorafenib Dose-Optimisation in Patients With Refractory Metastatic Colorectal Cancer (ReDOS): A Randomised, Multicentre, Open-Label, Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/31262657/
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial https://pubmed.ncbi.nlm.nih.gov/33604969/
Fruquintinib Versus Placebo in Patients With Refractory Metastatic Colorectal Cancer (FRESCO-2): An International, Multicentre, Randomised, Double-Blind, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/37331369/
Targeting KRAS in Cancer https://pubmed.ncbi.nlm.nih.gov/38637634/
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/29946728/
-
Young-onset colorectal cancer is on the rise, challenging GI oncologists across the globe. Join Drs Benjamin Schlechter and Kimmie Ng as they share their expertise and experience.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000090. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines https://pubmed.ncbi.nlm.nih.gov/36549470/
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations https://pubmed.ncbi.nlm.nih.gov/37992266/
Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/31243121/
Evaluation of Genomic Alterations in Early-Onset Versus Late-Onset Colorectal Cancer https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3511
Young Onset Colorectal Cancer Patients Are Diagnosed With Advanced Disease After Multiple Misdiagnoses https://aacrjournals.org/cancerres/article/79/13_Supplement/3347/635227/Abstract-3347-Young-onset-colorectal-cancer
Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women https://pubmed.ncbi.nlm.nih.gov/30326010/
Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/30740587/
Sugar-Sweetened Beverage Intake in Adulthood and Adolescence and Risk of Early-Onset Colorectal Cancer Among Women https://pubmed.ncbi.nlm.nih.gov/33958435/
A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers https://pubmed.ncbi.nlm.nih.gov/34405229/
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405 https://pubmed.ncbi.nlm.nih.gov/34636852/
Overtreatment of Young Adults With Colon Cancer: More Intense Treatments With Unmatched Survival Gains https://pubmed.ncbi.nlm.nih.gov/25806815/
-
Are you using liquid biopsies in your practice? Join Drs Benjamin Schlechter and Pashtoon Kasi as they review the latest clinical applications of ctDNA and liquid biopsies in colorectal cancer.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000089. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Colon Cancer https://emedicine.medscape.com/article/277496-overview
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices https://pubmed.ncbi.nlm.nih.gov/35839443/
Methylomics and Cancer: The Current State of Methylation Profiling and Marker Development for Clinical Care https://pubmed.ncbi.nlm.nih.gov/37840147/
Circulating Tumor DNA (ctDNA) for Informing Adjuvant Chemotherapy (ACT) in Stage II/III Colorectal Cancer (CRC): Interim Analysis of BESPOKE CRC Study https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.9
Molecular Residual Disease and Efficacy of Adjuvant Chemotherapy in Patients With Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/36646802/
CIRCULATE-Japan: Circulating Tumor DNA-Guided Adaptive Platform Trials to Refine Adjuvant Therapy for Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/33931919/
Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US https://pubmed.ncbi.nlm.nih.gov/36260786/
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer https://pubmed.ncbi.nlm.nih.gov/35657320/
Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients With Stage 2a Colon Cancer (COBRA) https://pubmed.ncbi.nlm.nih.gov/33999346/
Clonal Hematopoiesis Detection in Patients With Cancer Using Cell-Free DNA Sequencing https://pubmed.ncbi.nlm.nih.gov/36989374/
Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors https://pubmed.ncbi.nlm.nih.gov/34725800/
The PEGASUS Trial: Post-Surgical Liquid Biopsy-Guided Treatment of Stage III and High-Risk Stage II Colon Cancer Patients https://www.annalsofoncology.org/article/S0923-7534(23)04164-9/fulltext
Microsatellite Instability: A Review of What the Oncologist Should Know https://pubmed.ncbi.nlm.nih.gov/31956294/
Utility and Debate of Liquid Biopsy Assays in Surveillance Setting https://dailynews.ascopubs.org/do/utility-and-debate-liquid-biopsy-assays-surveillance-setting
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial https://pubmed.ncbi.nlm.nih.gov/34541864/
-
Join experts Drs Benjamin Schlechter and Diane Saverese as they discuss systemic therapy for advanced colorectal cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988974). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Characterization of Two Metastatic Subpopulations Originating From a Single Human Colon Carcinoma https://pubmed.ncbi.nlm.nih.gov/6861147/
The Phenomenon of Pleiotropic Drug Resistance https://pubmed.ncbi.nlm.nih.gov/3331384/
Early Memories of Burton "Bud" Rose, Founder of UpToDate — and Medical Education Visionary https://blogs.jwatch.org/hiv-id-observations/index.php/early-memories-of-burton-bud-rose-founder-of-uptodate-and-medical-education-visionary/2020/05/06/
Combining Chemotherapy and Targeted Therapies in Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/17990352/
Addition of Cetuximab to Oxaliplatin-Based First-Line Combination Chemotherapy for Treatment of Advanced Colorectal Cancer: Results of the Randomised Phase 3 MRC COIN Trial https://pubmed.ncbi.nlm.nih.gov/21641636/
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? https://pubmed.ncbi.nlm.nih.gov/28214977/
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) https://pubmed.ncbi.nlm.nih.gov/30552157/
FOLFOXIRI Plus Bevacizumab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment of Patients With Metastatic Colorectal Cancer: Updated Overall Survival and Molecular Subgroup Analyses of the Open-Label, Phase 3 TRIBE Study https://pubmed.ncbi.nlm.nih.gov/26338525/
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/23881988/
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/19339720/
Final Results From PRIME: Randomized Phase III Study of Panitumumab With FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/24718886/
FOLFIRI Plus Cetuximab or Bevacizumab for Advanced Colorectal Cancer: Final Survival and Per-Protocol Analysis of FIRE-3, A Randomised Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33154570/
FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment for Patients With Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/25088940/
Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong? https://pubmed.ncbi.nlm.nih.gov/30545999/
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/34061178/
Effect of Duration of Adjuvant Chemotherapy for Patients With Stage III Colon Cancer (IDEA Collaboration): Final Results From a Prospective, Pooled Analysis of Six Randomised, Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/33271092/
Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance) https://pubmed.ncbi.nlm.nih.gov/30688523/
The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials https://pubmed.ncbi.nlm.nih.gov/31855256/
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial https://pubmed.ncbi.nlm.nih.gov/34516759/
-
How do you know if your patient will benefit from liver-directed therapy for colorectal cancer? Join experts Drs Benjamin Schlechter and Ammar Sarwar as they discuss.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988973). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Colon Cancer https://emedicine.medscape.com/article/277496-overview
Locoregional Liver-directed Therapies to Treat Unresectable Colorectal Liver Metastases: A Review https://pubmed.ncbi.nlm.nih.gov/35180338/
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/30621040/
SIRFLOX: Randomized Phase III Trial Comparing First-line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/26903575/
First-line Selective Internal Radiotherapy Plus Chemotherapy Versus Chemotherapy Alone in Patients With Liver Metastases From Colorectal Cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A Combined Analysis of Three Multicentre, Randomised, Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/28781171/
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-label, International, Multicenter, Phase III Trial https://pubmed.ncbi.nlm.nih.gov/34541864/
FOLFOX Regimen https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfox-regimen
FOLFIRI (Folinic Acid, Fluorouracil, and Irinotecan) Increases not Efficacy but Toxicity Compared With Single-agent Irinotecan as a Second-line Treatment in Metastatic Colorectal Cancer Patients: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/35069808/
Hepatic Chemoembolization https://www.ncbi.nlm.nih.gov/books/NBK507822/
Post-embolization Syndrome as an Early Predictor of Overall Survival After Transarterial Chemoembolization for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/26374137/
When Should You Consider Immunotherapy in Colorectal Cancer https://www.medscape.com/viewarticle/986437
FOLFOXIRI Reintroduction in Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/32164907/
A Review of Applying Transarterial Chemoembolization (TACE) Method for Management of Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/34934646/
Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data https://pubmed.ncbi.nlm.nih.gov/26765068/
-
Drs Benjamin L. Schlechter and John Strickler discuss the newest testing and treatment options for HER2-amplified colorectal cancer and the findings from the MOUNTAINEER and DESTINY-CRC studies.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988972). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study https://pubmed.ncbi.nlm.nih.gov/26610798/
Tucatinib Plus Trastuzumab for Chemotherapy-Refractory, HER2-Positive, RAS Wild-Type Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER): A Multicentre, Open-Label, Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/37142372/
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients With Advanced Solid Tumors https://pubmed.ncbi.nlm.nih.gov/32127466/
Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification From Aneuploidy in Diverse Advanced Cancers https://pubmed.ncbi.nlm.nih.gov/34677235/
109P – Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis From Japan and the United States https://www.sciencedirect.com/science/article/pii/S0923753419583405
COLONTOWN https://colontown.org/colontown-on-facebook/
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target https://pubmed.ncbi.nlm.nih.gov/35580290/
4795 – Trastuzumab and Tucatinib for the Treatment of HER2 Amplified Metastatic Colorectal Cancer (mCRC): Initial Results From the MOUNTAINEER Trial https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/Trastuzumab-and-tucatinib-for-the-treatment-of-HER2-amplified-metastatic-colorectal-cancer-mCRC-Initial-results-from-the-MOUNTAINEER-trial
Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline https://www.businesswire.com/news/home/20180131005494/en/Seattle-Genetics-to-Acquire-Cascadian-Therapeutics-Adding-Late-Stage-Breast-Cancer-Program-to-Its-Oncology-Pipeline
Trastuzumab Deruxtecan (T-DXd) Versus Treatment of Physician's Choice (TPC) in Patients (Pts) With HER2-Low Unresectable and/or Metastatic Breast Cancer (mBC): Results of DESTINY-Breast04, a Randomized, Phase 3 Study https://meetings.asco.org/abstracts-presentations/209021
DESTINY-Breast04 Establishes Trastuzumab Deruxtecan as a New Standard of Care for HER2-Low Metastatic Breast Cancer https://dailynews.ascopubs.org/do/destiny-breast04-establishes-trastuzumab-deruxtecan-new-standard-care-her2-low
Final Results of DESTINY-CRC01 Investigating Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/37286557/
Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Overexpressing/Amplified (HER2+) Metastatic Colorectal Cancer (mCRC): Primary Results From the Multicenter, Randomized, Phase 2 DESTINY-CRC02 Study https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.3501?af=R
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/35837349/
KRASG12C Inhibition With Sotorasib in Advanced Solid Tumors https://pubmed.ncbi.nlm.nih.gov/32955176/
315O – Sotorasib in Combination With Panitumumab in Refractory KRASG12C-Mutated Colorectal Cancer: Safety and Efficacy for Phase Ib Full Expansion Cohort https://oncologypro.esmo.org/meeting-resources/esmo-congress/sotorasib-in-combination-with-panitumumab-in-refractory-kras-g12c-mutated-colorectal-cancer-safety-and-efficacy-for-phase-ib-full-expansion-cohort
-
Join Drs Benjamin Schlechter and Harvey Mamon as they discuss treatment options for patients with stage II and III rectal cancer based on new data from the most recent clinical trial results.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988971). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Colon Cancer https://emedicine.medscape.com/article/277496-overview
Colon Cancer Staging https://emedicine.medscape.com/article/2006674-overview
Signal Transduction https://www.cancer.gov/publications/dictionaries/cancer-terms/def/signal-transduction
Preoperative Treatment of Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/37272534/
Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial https://pubmed.ncbi.nlm.nih.gov/24419115/
FOLFOX Regimen https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfox-regimen
Cancer Therapy Evaluation Program https://ctep.cancer.gov/
Common Terminology Criteria for Adverse Events (CTCAE) v5.0 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) https://pubmed.ncbi.nlm.nih.gov/37270691/
Abdominoperineal Resection https://www.ncbi.nlm.nih.gov/books/NBK574568/
The Circumferential Resection Margin Is a Prognostic Predictor in Colon Cancer https://pubmed.ncbi.nlm.nih.gov/32670875/
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy https://pubmed.ncbi.nlm.nih.gov/35483010/
Total Neoadjuvant Therapy (TNT) Versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33987952/
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS) https://classic.clinicaltrials.gov/ct2/show/NCT05610163
Factors Influencing Downstaging After Neoadjuvant Long-Course Chemoradiotherapy in Rectal Carcinoma https://pubmed.ncbi.nlm.nih.gov/35545701/
Carcinoembryonic Antigen https://www.ncbi.nlm.nih.gov/books/NBK578172/
Short-Course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33301740/
Neoadjuvant Chemotherapy With FOLFIRINOX and Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33862000/
FOLFIRINOX Regimen https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfirinox-regimen
Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery - A Five-Year Follow-Up of the RAPIDO Trial https://pubmed.ncbi.nlm.nih.gov/36661037/
-
When you see an older adult with colorectal cancer, how do you fit your care to their needs? Join Dr Benjamin Schlechter and geriatric medical oncology expert Dr Nadine McCleary for clinical pearls.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988970). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Colorectal Cancer https://www.medscape.com/viewarticle/776784
Comprehensive Geriatric Assessment--A Guide for the Non-specialist https://pubmed.ncbi.nlm.nih.gov/24118661/
Comprehensive Geriatric Assessment for Older Patients With Cancer https://pubmed.ncbi.nlm.nih.gov/17488980/
Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals https://pubmed.ncbi.nlm.nih.gov/31616281/
NCCN Guidelines https://www.nccn.org/guidelines/category_1
ePrognosis https://eprognosis.ucsf.edu/
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/29590544/
Oxaliplatin https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oxaliplatin
Colon Cancer Staging https://emedicine.medscape.com/article/2006674-overview
Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set https://pubmed.ncbi.nlm.nih.gov/18467725/
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07 https://pubmed.ncbi.nlm.nih.gov/17470851/
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer https://pubmed.ncbi.nlm.nih.gov/15175436/
Colon Cancer Medication https://emedicine.medscape.com/article/277496-medication
Capecitabine https://www.cancer.gov/publications/dictionaries/cancer-drug/def/capecitabine
The ARCAD Advanced Colorectal Cancer Database--Open for Business https://pubmed.ncbi.nlm.nih.gov/22104572/
Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years https://pubmed.ncbi.nlm.nih.gov/22665536/
FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data https://pubmed.ncbi.nlm.nih.gov/30878317/
Alliance for Clinical Trials in Oncology https://www.allianceforclinicaltrialsinoncology.org/main/
Cancer and Aging Research Group https://www.mycarg.org/
Effect of Duration of Adjuvant Chemotherapy for Patients With Stage III Colon Cancer (IDEA Collaboration): Final Results From a Prospective, Pooled Analysis of Six Randomised, Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/33271092/
Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer? https://ascopubs.org/doi/full/10.1200/JCO.2007.11.6582
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials | JNCI Cancer Spectrum | Oxford Academic (oup.com) https://academic.oup.com/jncics/article/6/2/pkac014/6537541
-
Keep up to date on the newest research and clinical application of immunotherapy treatments in colorectal cancer with leading experts Dr Benjamin Schlechter and Marwan Fakih.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986437). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Colorectal Cancer https://www.medscape.com/viewarticle/776784
Microsatellite Instability in Colorectal Cancer: Overview of Its Clinical Significance and Novel Perspectives https://pubmed.ncbi.nlm.nih.gov/30543589/
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/35660797/
Dostarlimab: The Miracle Drug for the Treatment of Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/36060435/
Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers https://pubmed.ncbi.nlm.nih.gov/32251400/
Lynch Syndrome https://www.ncbi.nlm.nih.gov/books/NBK431096/
Optimal Management of Low Anterior Resection Syndrome: Colorectal Cancer (Update) https://pubmed.ncbi.nlm.nih.gov/32730011/
Pembrolizumab (Rx) https://reference.medscape.com/drug/keytruda-pembrolizumab-999962
Carcinomatosis https://www.cancer.gov/publications/dictionaries/cancer-terms/def/carcinomatosis
Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study https://pubmed.ncbi.nlm.nih.gov/32919526/
Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/35427471/
Circulating Tumor DNA Test May Help Guide GI Cancer Management https://www.medscape.com/viewarticle/982900
Durvalumab and Tremelimumab Combination Therapy Versus Durvalumab or Tremelimumab Monotherapy for Patients With Solid Tumors: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/32664183/
FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial https://pubmed.ncbi.nlm.nih.gov/34970487/
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/34196693/
Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36892833/
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) https://pubmed.ncbi.nlm.nih.gov/32343640/
Regorafenib Plus Nivolumab in Patients With Mismatch Repair-Proficient/Microsatellite Stable Metastatic Colorectal Cancer: A Single-Arm, Open-Label, Multicentre Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/37090438/
CTLA-4 Cytotoxic T-Lymphocyte Associated Protein 4 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1493
iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics https://pubmed.ncbi.nlm.nih.gov/28271869/
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer https://clinicaltrials.gov/ct2/show/NCT03860272
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer https://clinicaltrials.gov/ct2/show/NCT05608044
